Eli Lilly announced successful Phase III data for its oral glucagon-like peptide 1 (GLP-1) receptor agonist, orforglipron, in adults with obesity or overweight and type 2 diabetes. The trial demonstrated significant weight reductions—up to 11% over 72 weeks—and meaningful improvements in glycemic control. Multiple dosing regimens met primary and key secondary endpoints, establishing orforglipron as a leading oral candidate in the competitive GLP-1 obesity treatment landscape.<BR><BR>Despite these results, concerns remain over side effects and patient tolerability compared to injectable competitors. Lilly is preparing a regulatory submission to seek FDA approval, trailing rivals in timing but capitalizing on oral administration convenience.